Mechanisms of improvement by the SGLT2 inhibitor for increased risk of atrial fibrillation via lipotoxicity.

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K11675
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 59040:Nutrition science and health science-related
• Research Institution: Tottori University
• Principal Investigator: SAWANO Tatsuya 鳥取大学, 医学部, 助教 (10813967)
• Co-Investigator(Kenkyū-buntansha): 三明 淳一朗 鳥取大学, 医学部, 准教授 (40372677)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 心房細動 / 肥満 / 脂肪毒性 / SGLT2阻害薬

Outline of Final Research Achievements

Obesity not only increases the risk of atrial fibrillation (AF), but current treatments for obesity-related AF have only limited effectiveness or are difficult to prevent AF recurrence. Therefore, there is a need to explore new therapeutic targets and develop new drugs.　Therefore, to clarify whether the SGLT2 inhibitor has an inhibitory effect on the increased inducibility of AF in obesity, we examined the effect of the SGLT2 inhibitor on the inducibility of AF in a high-fat diet-induced obese model. As a result, we found that the administration of SGLT2 inhibitors can inhibit the increased inducibility of AF in obesity.

Free Research Field

薬理学

Academic Significance and Societal Importance of the Research Achievements

心房細動の患者数は増加を続けている．心房細動は心不全や脳卒中などのリスクを増大させ，健康寿命を損なうことから治療が必要である．特に，心房細動のリスク因子である肥満は，世界的な健康問題となっており，心房細動患者の更なる増加に寄与すると考えられる．これまで心房細動を治療する手段は限られており，新たな治療法の開発は重要な課題である．本研究成果は，肥満に関連した心房細動治療においてSGLT2阻害薬が新たな選択肢となりうる可能性を示唆する．本研究をきっかけに，心房細動の治療・予防による健康寿命の延伸に繋がることが期待される．